Should tranexamic acid be given to a pediatric trauma patient with significant bleeding or at risk for hemorrhagic shock?

Yes, tranexamic acid (TXA) should be given to pediatric trauma patients with significant bleeding or at risk for hemorrhagic shock.

TXA can and should be administered to pediatric trauma patients who are bleeding or at risk of significant hemorrhage, using a loading dose of 15 mg/kg followed by an infusion of 2 mg/kg/h, and must be given within 3 hours of injury. 1

Dosing for Pediatric Patients

The pediatric-specific dosing differs from adult dosing and is weight-based:

• Loading dose: 15 mg/kg IV over 10 minutes
• Maintenance infusion: 2 mg/kg/h for 8 hours

This recommendation comes directly from the 2016 AAGBI guidelines, which explicitly state that "tranexamic acid can be used in children" with this specific dosing regimen for trauma 1. The FDA label confirms limited but supportive data in pediatric patients, noting no significant pharmacokinetic differences between adults and children 2.

Critical Timing Window

TXA must be administered within 3 hours of injury. This is non-negotiable based on adult trauma data from CRASH-2 that showed:

• Treatment ≤1 hour: 32% reduction in bleeding deaths
• Treatment 1-3 hours: 21% reduction in bleeding deaths
• Treatment >3 hours: 44% increase in bleeding deaths 3

While this timing data comes from adult studies, the European guidelines and AAGBI apply these principles to pediatric patients until pediatric-specific data emerges 1, 3.

Who Should Receive TXA

Administer TXA to pediatric trauma patients with:

• Clinical signs of hemorrhagic shock (hypotension, tachycardia)
• Active bleeding or high risk of significant hemorrhage
• Presentation within 3 hours of injury

The 2023 European guideline (Grade 1A recommendation) supports early TXA administration "as soon as possible, if feasible en route to the hospital" for trauma patients bleeding or at risk of significant hemorrhage 4. While this is primarily adult data, the AAGBI explicitly extends trauma resuscitation principles to children with appropriate weight-based adjustments 1.

Safety Profile in Pediatrics

TXA appears safe in pediatric trauma patients. A 2023 Israeli Defense Forces study of 70 pediatric trauma patients receiving prehospital TXA found zero adverse events (upper 95% CI limit: 4.3%) 5. The 2019 review of TXA in pediatric perioperative settings confirms it is "well-tolerated and effective" 6. The FDA label notes limited pediatric data but no safety signals suggesting different responses than adults 2.

Common concerns about thrombosis have not materialized—CRASH-2 actually showed lower thrombotic event rates with TXA 3. Seizure risk exists at high doses (seen in cardiac surgery) but not at trauma dosing 3.

Evidence Limitations and Clinical Reality

The major caveat: there are no large randomized trials of TXA specifically in pediatric trauma. The 2023 propensity-matched Israeli study (n=70 pediatric TXA patients) failed to show mortality benefit, though it was underpowered and couldn't exclude benefit 5. The 2021 U.S. survey found only 35% of trauma centers treating pediatric patients use TXA, with variable dosing practices 7.

However, given:

1. Strong adult trauma mortality benefit (CRASH-2: 1.5% absolute mortality reduction) 3
2. Proven efficacy in pediatric elective surgery 6, 7
3. Excellent safety profile 5, 6
4. Low cost and ease of administration
5. Explicit guideline support for pediatric use 1

The risk-benefit calculation strongly favors TXA administration in bleeding pediatric trauma patients.

Practical Implementation

1. Identify candidates: Pediatric trauma patient with SBP <90 mmHg (age-adjusted), HR >110/min, or clinical suspicion of significant bleeding
2. Check timing: Injury occurred <3 hours ago
3. Administer: 15 mg/kg IV bolus over 10 minutes, followed by 2 mg/kg/h infusion for 8 hours
4. Document clearly: Communicate TXA administration to receiving hospital to avoid duplicate dosing 8, 9
5. Do not delay for coagulation testing: Give empirically based on clinical presentation 4

Common Pitfalls

• Giving adult fixed dose (1g) to children: Use weight-based dosing (15 mg/kg)
• Administering >3 hours post-injury: May increase mortality; avoid unless point-of-care testing shows hyperfibrinolysis 1, 3
• Waiting for laboratory confirmation: TXA should be given based on clinical assessment, not lab results 4
• Failing to communicate administration: Receiving facilities need to know to avoid duplicate dosing and monitor appropriately 8

The 2025 joint NAEMSP/ACEP/ACS-COT position statement acknowledges that "the role of prehospital TXA in pediatric trauma patients with clinical signs of hemorrhagic shock has not been studied, and standardized dosing has not been established," but recommends that "if used, it should be given within 3 hours of injury" 8. This reflects the reality that while pediatric-specific evidence is limited, the biological plausibility, adult data, and safety profile support use in critically bleeding children.